Print Page  Close Window
Receive E-mail AlertsE-mail Alerts
Keyword Search
2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008
DateTitle 
04/07/14Alnylam’s McSwiggen Patent Upheld in European Opposition Proceedings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 7, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Patent Office (EPO) has upheld the McSwiggen EP 1423406 (’406) patent in oral opposition proceedings in Munich, Germany. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving “drug-like” propertie... 
Printer Friendly Version
04/02/14Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ALN-TTRsc for designation as an orphan medicinal product for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR). “We are very pleased to have ... 
Printer Friendly Version
04/02/14Alnylam to Webcast Presentation at 13th Annual Needham Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 2, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 13th Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 12:50 p.m. ET at the Westin Grand Central Hotel in New York City. A live audio webcast of the presentation will be available on the Investors section of the co... 
Printer Friendly Version
03/26/14Genzyme Exercises its Right to Purchase Additional Shares of Alnylam Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 26, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that Genzyme, a Sanofi company, has exercised its right to purchase 344,448 unregistered shares of Alnylam’s common stock in accordance with the terms of an investor rights agreement between Alnylam and Genzyme, dated January 11, 2014. These shares became available for purchase by Genzyme as a result... 
Printer Friendly Version
03/21/14Alnylam to Present Data from its RNAi Therapeutic Programs Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) at XIVth International Symposium on Amyloidosis (ISA)
– Presentations Include Results of 283-Patient Natural History Study of ATTR Patients with Familial Amyloidotic Polyneuropathy (FAP) – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that its scientists and collaborators will present pre-clinical and clinical data with patisiran (ALN-TTR02) and ALN-TTRsc – RNAi therapeutics targeting transthyr... 
Printer Friendly Version
03/06/14Alnylam Announces Closing of Previously Announced Acquisition of Merck’s Sirna Therapeutics Subsidiary
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna Therapeutics” or “Sirna”) has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant... 
Printer Friendly Version
03/06/14Alnylam to Webcast Presentation at Barclays Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Thursday, March 13, 2014 at 10:45 a.m. ET at the Loews Miami Hotel in Miami, Florida. A live audio webcast of the presentation will be available on the Investors section of the company’s website, ww... 
Printer Friendly Version
02/27/14Alnylam Announces Closing of Previously Announced Alliance with Genzyme for Discovery, Development, and Commercialization of RNAi Therapeutics as Genetic Medicines
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 27, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the previously announced alliance with Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) has closed, following the expiration of the Hart-Scott-Rodino waiting period. The two companies formed the collaboration for the development and commercialization of RNAi therapeutics as genetic medici... 
Printer Friendly Version
02/25/14Alnylam to Webcast Presentation at Cowen and Company 34th Annual Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 11:20 a.m. ET at The Boston Marriott Copley Place in Boston. A live audio webcast of the presentation will be available on the Investors section of t... 
Printer Friendly Version
02/13/14Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Period Activities
– Announced Major Business Transactions Including Transformational Alliance with Genzyme for RNAi Therapeutics as Genetic Medicines and Acquisition of Merck RNAi Assets and Sirna Therapeutics Subsidiary – – Initiated APOLLO Phase 3 Study with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP) – – Initiated Phase 2 Study with ALN-TTRsc in ATT... 
Printer Friendly Version
02/06/14Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2013 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the fourth quarter and year ending December 31, 2013 on Thursday, February 13, 2014, after the U.S. financial markets close. Management will provide an update on the company, discuss fourth quarter and year-end 2013 results, and discuss expectations fo... 
Printer Friendly Version
02/04/14Alnylam to Webcast Presentation at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. ET at the Waldorf Astoria in New York City. In addition, Alnylam management will present a company overview at the 2014 Leerink Global Healthca... 
Printer Friendly Version
01/22/14Alnylam Initiates Phase 1 Clinical Trial with ALN-AT3, a Subcutaneously Administered RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
- Company Expects to Present Initial Data from Phase 1 Study in Late 2014- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 22, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated a Phase 1 study with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD). ALN-AT3 has demonstra... 
Printer Friendly Version
01/13/14Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases
- Genzyme to Obtain Significant Global Rights to Alnylam’s Pipeline - - Alnylam Retains Most Product Rights in North America and Western Europe - - Genzyme Becomes Major Alnylam Shareholder through $700 Million Equity Investment - PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2014-- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced today that the... 
Printer Friendly Version
01/13/14Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
- New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medicine Pipeline, Including “Alnylam 5x15” Programs - - Alnylam Retains Broad Product Rights in North America and Western Europe and Genzyme Obtains Rights to Access Alnylam’s Genetic Medicines Pipeline in the Rest of World and Receives Co-Development, Co-Commercialization Rights or Global Rights to 3 Programs - - Genzyme Become... 
Printer Friendly Version
01/12/14Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
– Strategic Transaction Positions RNAi Assets for Future Advancement through Alnylam’s Commitment to RNAi Therapeutics – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today the acquisition of Merck’s wholly owned subsidiary Sirna Therapeutics, Inc. (“Sirna Therapeutics”), comprising intellectual property and RNAi assets including pre-clinical therapeutic ... 
Printer Friendly Version
01/10/14Alnylam Provides Key 2014 Goals for RNAi Therapeutics Pipeline
- Expects to Exceed “Alnylam 5x15” Guidance; Now Plans to Have 6 to 7 Programs in Clinical Development by End of 2015, Including at Least 2 in Phase 3 and 5 to 6 with Human Proof-of-Concept Data - - Focused on Enrolling Patients in APOLLO Phase 3 with Patisiran (ALN-TTR02) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR) in Patients with Familial Amyloidotic Polyneuropathy (FAP), with Initial Data from Phase 2 Open-Label Exten... 
Printer Friendly Version
01/06/14Alnylam to Webcast Presentation at 32nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2014-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014 at 11:30 a.m. PT (2:30 p.m. ET) at the Westin St. Francis Hotel in San Francisco, Calif. This presentation will include a review of the company’s goals and guidance. ... 
Printer Friendly Version

This part of our website contains archived information which should not be considered current and may no longer be accurate.